Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Growth (Status and Outlook) 2022-2028
Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families.
The global market for Treatment of Chemotherapy-Induced Nausea in Cancer Patients is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Treatment of Chemotherapy-Induced Nausea in Cancer Patients market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Treatment of Chemotherapy-Induced Nausea in Cancer Patients market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Treatment of Chemotherapy-Induced Nausea in Cancer Patients market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Treatment of Chemotherapy-Induced Nausea in Cancer Patients market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Treatment of Chemotherapy-Induced Nausea in Cancer Patients players cover Heron Therapeutics, Merck, Eisai, Mundipharma and Qilu Pharma, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Treatment of Chemotherapy-Induced Nausea in Cancer Patients market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Treatment of Chemotherapy-Induced Nausea in Cancer Patients market, with both quantitative and qualitative data, to help readers understand how the Treatment of Chemotherapy-Induced Nausea in Cancer Patients market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions.
Market Segmentation:
The study segments the Treatment of Chemotherapy-Induced Nausea in Cancer Patients market and forecasts the market size by Type (5-HT3 Inhibitors, NK1 Inhibitors and Other), by Application (Acute CINV, Delayed CINV, Breakthrough CINV and Others), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
5-HT3 Inhibitors
NK1 Inhibitors
Other
Segmentation by application
Acute CINV
Delayed CINV
Breakthrough CINV
Others
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Heron Therapeutics
Merck
Eisai
Mundipharma
Qilu Pharma
Teva
Novartis
Roche
Mylan
Baxter
GSK
Helsinn
Southwest Pharma
Haisco
Sun Pharma
Chapter Introduction
Chapter 1: Scope of Treatment of Chemotherapy-Induced Nausea in Cancer Patients, Research Methodology, etc.
Chapter 2: Executive Summary, global Treatment of Chemotherapy-Induced Nausea in Cancer Patients market size and CAGR, Treatment of Chemotherapy-Induced Nausea in Cancer Patients market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Treatment of Chemotherapy-Induced Nausea in Cancer Patients revenue, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, revenue segment by country, by type, and application.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients market size forecast by region, by country, by type, and application
Chapter 13: Comprehensive company profiles of the leading players, including Heron Therapeutics, Merck, Eisai, Mundipharma, Qilu Pharma, Teva, Novartis, Roche and Mylan, etc.
Chapter 14: Research Findings and Conclusion
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size 2017-2028
2.1.2 Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size CAGR by Region 2017 VS 2022 VS 2028
2.2 Treatment of Chemotherapy-Induced Nausea in Cancer Patients Segment by Type
2.2.1 5-HT3 Inhibitors
2.2.2 NK1 Inhibitors
2.2.3 Other
2.3 Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Type
2.3.1 Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size CAGR by Type (2017 VS 2022 VS 2028)
2.3.2 Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share by Type (2017-2022)
2.4 Treatment of Chemotherapy-Induced Nausea in Cancer Patients Segment by Application
2.4.1 Acute CINV
2.4.2 Delayed CINV
2.4.3 Breakthrough CINV
2.4.4 Others
2.5 Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Application
2.5.1 Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size CAGR by Application (2017 VS 2022 VS 2028)
2.5.2 Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share by Application (2017-2022)
3 Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Player
3.1 Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share by Players
3.1.1 Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue by Players (2020-2022)
3.1.2 Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue Market Share by Players (2020-2022)
3.2 Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Treatment of Chemotherapy-Induced Nausea in Cancer Patients by Regions
4.1 Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Regions (2017-2022)
4.2 Americas Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Growth (2017-2022)
4.3 APAC Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Growth (2017-2022)
4.4 Europe Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Growth (2017-2022)
4.5 Middle East & Africa Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Growth (2017-2022)
5 Americas
5.1 Americas Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Country (2017-2022)
5.2 Americas Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Type (2017-2022)
5.3 Americas Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Application (2017-2022)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Region (2017-2022)
6.2 APAC Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Type (2017-2022)
6.3 APAC Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Application (2017-2022)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Treatment of Chemotherapy-Induced Nausea in Cancer Patients by Country (2017-2022)
7.2 Europe Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Type (2017-2022)
7.3 Europe Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Application (2017-2022)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Treatment of Chemotherapy-Induced Nausea in Cancer Patients by Region (2017-2022)
8.2 Middle East & Africa Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Type (2017-2022)
8.3 Middle East & Africa Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Application (2017-2022)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
10.1 Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Forecast by Regions (2023-2028)
10.1.1 Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Forecast by Regions (2023-2028)
10.1.2 Americas Treatment of Chemotherapy-Induced Nausea in Cancer Patients Forecast
10.1.3 APAC Treatment of Chemotherapy-Induced Nausea in Cancer Patients Forecast
10.1.4 Europe Treatment of Chemotherapy-Induced Nausea in Cancer Patients Forecast
10.1.5 Middle East & Africa Treatment of Chemotherapy-Induced Nausea in Cancer Patients Forecast
10.2 Americas Treatment of Chemotherapy-Induced Nausea in Cancer Patients Forecast by Country (2023-2028)
10.2.1 United States Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
10.2.2 Canada Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
10.2.3 Mexico Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
10.2.4 Brazil Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
10.3 APAC Treatment of Chemotherapy-Induced Nausea in Cancer Patients Forecast by Region (2023-2028)
10.3.1 China Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
10.3.2 Japan Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
10.3.3 Korea Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
10.3.4 Southeast Asia Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
10.3.5 India Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
10.3.6 Australia Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
10.4 Europe Treatment of Chemotherapy-Induced Nausea in Cancer Patients Forecast by Country (2023-2028)
10.4.1 Germany Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
10.4.2 France Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
10.4.3 UK Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
10.4.4 Italy Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
10.4.5 Russia Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
10.5 Middle East & Africa Treatment of Chemotherapy-Induced Nausea in Cancer Patients Forecast by Region (2023-2028)
10.5.1 Egypt Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
10.5.2 South Africa Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
10.5.3 Israel Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
10.5.4 Turkey Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
10.5.5 GCC Countries Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Forecast
10.6 Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Forecast by Type (2023-2028)
10.7 Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Forecast by Application (2023-2028)
11 Key Players Analysis
11.1 Heron Therapeutics
11.1.1 Heron Therapeutics Company Information
11.1.2 Heron Therapeutics Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
11.1.3 Heron Therapeutics Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue, Gross Margin and Market Share (2020-2022)
11.1.4 Heron Therapeutics Main Business Overview
11.1.5 Heron Therapeutics Latest Developments
11.2 Merck
11.2.1 Merck Company Information
11.2.2 Merck Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
11.2.3 Merck Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue, Gross Margin and Market Share (2020-2022)
11.2.4 Merck Main Business Overview
11.2.5 Merck Latest Developments
11.3 Eisai
11.3.1 Eisai Company Information
11.3.2 Eisai Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
11.3.3 Eisai Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue, Gross Margin and Market Share (2020-2022)
11.3.4 Eisai Main Business Overview
11.3.5 Eisai Latest Developments
11.4 Mundipharma
11.4.1 Mundipharma Company Information
11.4.2 Mundipharma Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
11.4.3 Mundipharma Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue, Gross Margin and Market Share (2020-2022)
11.4.4 Mundipharma Main Business Overview
11.4.5 Mundipharma Latest Developments
11.5 Qilu Pharma
11.5.1 Qilu Pharma Company Information
11.5.2 Qilu Pharma Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
11.5.3 Qilu Pharma Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue, Gross Margin and Market Share (2020-2022)
11.5.4 Qilu Pharma Main Business Overview
11.5.5 Qilu Pharma Latest Developments
11.6 Teva
11.6.1 Teva Company Information
11.6.2 Teva Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
11.6.3 Teva Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue, Gross Margin and Market Share (2020-2022)
11.6.4 Teva Main Business Overview
11.6.5 Teva Latest Developments
11.7 Novartis
11.7.1 Novartis Company Information
11.7.2 Novartis Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
11.7.3 Novartis Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue, Gross Margin and Market Share (2020-2022)
11.7.4 Novartis Main Business Overview
11.7.5 Novartis Latest Developments
11.8 Roche
11.8.1 Roche Company Information
11.8.2 Roche Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
11.8.3 Roche Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue, Gross Margin and Market Share (2020-2022)
11.8.4 Roche Main Business Overview
11.8.5 Roche Latest Developments
11.9 Mylan
11.9.1 Mylan Company Information
11.9.2 Mylan Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
11.9.3 Mylan Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue, Gross Margin and Market Share (2020-2022)
11.9.4 Mylan Main Business Overview
11.9.5 Mylan Latest Developments
11.10 Baxter
11.10.1 Baxter Company Information
11.10.2 Baxter Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
11.10.3 Baxter Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue, Gross Margin and Market Share (2020-2022)
11.10.4 Baxter Main Business Overview
11.10.5 Baxter Latest Developments
11.11 GSK
11.11.1 GSK Company Information
11.11.2 GSK Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
11.11.3 GSK Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue, Gross Margin and Market Share (2020-2022)
11.11.4 GSK Main Business Overview
11.11.5 GSK Latest Developments
11.12 Helsinn
11.12.1 Helsinn Company Information
11.12.2 Helsinn Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
11.12.3 Helsinn Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue, Gross Margin and Market Share (2020-2022)
11.12.4 Helsinn Main Business Overview
11.12.5 Helsinn Latest Developments
11.13 Southwest Pharma
11.13.1 Southwest Pharma Company Information
11.13.2 Southwest Pharma Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
11.13.3 Southwest Pharma Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue, Gross Margin and Market Share (2020-2022)
11.13.4 Southwest Pharma Main Business Overview
11.13.5 Southwest Pharma Latest Developments
11.14 Haisco
11.14.1 Haisco Company Information
11.14.2 Haisco Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
11.14.3 Haisco Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue, Gross Margin and Market Share (2020-2022)
11.14.4 Haisco Main Business Overview
11.14.5 Haisco Latest Developments
11.15 Sun Pharma
11.15.1 Sun Pharma Company Information
11.15.2 Sun Pharma Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
11.15.3 Sun Pharma Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue, Gross Margin and Market Share (2020-2022)
11.15.4 Sun Pharma Main Business Overview
11.15.5 Sun Pharma Latest Developments
12 Research Findings and Conclusion
Tables and Figures
List of Tables
Table 1. Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size CAGR by Region (2017 VS 2022 VS 2028) & ($ Millions)
Table 2. Major Players of 5-HT3 Inhibitors
Table 3. Major Players of NK1 Inhibitors
Table 4. Major Players of Other
Table 5. Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size CAGR by Type (2017 VS 2022 VS 2028) & ($ Millions)
Table 6. Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Type (2017-2022) & ($ Millions)
Table 7. Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share by Type (2017-2022)
Table 8. Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size CAGR by Application (2017 VS 2022 VS 2028) & ($ Millions)
Table 9. Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Application (2017-2022) & ($ Millions)
Table 10. Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share by Application (2017-2022)
Table 11. Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue by Players (2020-2022) & ($ Millions)
Table 12. Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue Market Share by Player (2020-2022)
Table 13. Treatment of Chemotherapy-Induced Nausea in Cancer Patients Key Players Head office and Products Offered
Table 14. Treatment of Chemotherapy-Induced Nausea in Cancer Patients Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Regions 2017-2022 & ($ Millions)
Table 18. Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share by Regions (2017-2022)
Table 19. Americas Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Country (2017-2022) & ($ Millions)
Table 20. Americas Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share by Country (2017-2022)
Table 21. Americas Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Type (2017-2022) & ($ Millions)
Table 22. Americas Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share by Type (2017-2022)
Table 23. Americas Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Application (2017-2022) & ($ Millions)
Table 24. Americas Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share by Application (2017-2022)
Table 25. APAC Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Region (2017-2022) & ($ Millions)
Table 26. APAC Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share by Region (2017-2022)
Table 27. APAC Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Type (2017-2022) & ($ Millions)
Table 28. APAC Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share by Type (2017-2022)
Table 29. APAC Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Application (2017-2022) & ($ Millions)
Table 30. APAC Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share by Application (2017-2022)
Table 31. Europe Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Country (2017-2022) & ($ Millions)
Table 32. Europe Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share by Country (2017-2022)
Table 33. Europe Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Type (2017-2022) & ($ Millions)
Table 34. Europe Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share by Type (2017-2022)
Table 35. Europe Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Application (2017-2022) & ($ Millions)
Table 36. Europe Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share by Application (2017-2022)
Table 37. Middle East & Africa Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Region (2017-2022) & ($ Millions)
Table 38. Middle East & Africa Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share by Region (2017-2022)
Table 39. Middle East & Africa Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Type (2017-2022) & ($ Millions)
Table 40. Middle East & Africa Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share by Type (2017-2022)
Table 41. Middle East & Africa Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Application (2017-2022) & ($ Millions)
Table 42. Middle East & Africa Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share by Application (2017-2022)
Table 43. Key Market Drivers & Growth Opportunities of Treatment of Chemotherapy-Induced Nausea in Cancer Patients
Table 44. Key Market Challenges & Risks of Treatment of Chemotherapy-Induced Nausea in Cancer Patients
Table 45. Key Industry Trends of Treatment of Chemotherapy-Induced Nausea in Cancer Patients
Table 46. Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Forecast by Regions (2023-2028) & ($ Millions)
Table 47. Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share Forecast by Regions (2023-2028)
Table 48. Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Forecast by Type (2023-2028) & ($ Millions)
Table 49. Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share Forecast by Type (2023-2028)
Table 50. Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Forecast by Application (2023-2028) & ($ Millions)
Table 51. Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share Forecast by Application (2023-2028)
Table 52. Heron Therapeutics Details, Company Type, Treatment of Chemotherapy-Induced Nausea in Cancer Patients Area Served and Its Competitors
Table 53. Heron Therapeutics Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
Table 54. Heron Therapeutics Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 55. Heron Therapeutics Main Business
Table 56. Heron Therapeutics Latest Developments
Table 57. Merck Details, Company Type, Treatment of Chemotherapy-Induced Nausea in Cancer Patients Area Served and Its Competitors
Table 58. Merck Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
Table 59. Merck Main Business
Table 60. Merck Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 61. Merck Latest Developments
Table 62. Eisai Details, Company Type, Treatment of Chemotherapy-Induced Nausea in Cancer Patients Area Served and Its Competitors
Table 63. Eisai Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
Table 64. Eisai Main Business
Table 65. Eisai Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 66. Eisai Latest Developments
Table 67. Mundipharma Details, Company Type, Treatment of Chemotherapy-Induced Nausea in Cancer Patients Area Served and Its Competitors
Table 68. Mundipharma Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
Table 69. Mundipharma Main Business
Table 70. Mundipharma Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 71. Mundipharma Latest Developments
Table 72. Qilu Pharma Details, Company Type, Treatment of Chemotherapy-Induced Nausea in Cancer Patients Area Served and Its Competitors
Table 73. Qilu Pharma Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
Table 74. Qilu Pharma Main Business
Table 75. Qilu Pharma Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 76. Qilu Pharma Latest Developments
Table 77. Teva Details, Company Type, Treatment of Chemotherapy-Induced Nausea in Cancer Patients Area Served and Its Competitors
Table 78. Teva Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
Table 79. Teva Main Business
Table 80. Teva Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 81. Teva Latest Developments
Table 82. Novartis Details, Company Type, Treatment of Chemotherapy-Induced Nausea in Cancer Patients Area Served and Its Competitors
Table 83. Novartis Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
Table 84. Novartis Main Business
Table 85. Novartis Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 86. Novartis Latest Developments
Table 87. Roche Details, Company Type, Treatment of Chemotherapy-Induced Nausea in Cancer Patients Area Served and Its Competitors
Table 88. Roche Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
Table 89. Roche Main Business
Table 90. Roche Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 91. Roche Latest Developments
Table 92. Mylan Details, Company Type, Treatment of Chemotherapy-Induced Nausea in Cancer Patients Area Served and Its Competitors
Table 93. Mylan Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
Table 94. Mylan Main Business
Table 95. Mylan Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 96. Mylan Latest Developments
Table 97. Baxter Details, Company Type, Treatment of Chemotherapy-Induced Nausea in Cancer Patients Area Served and Its Competitors
Table 98. Baxter Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
Table 99. Baxter Main Business
Table 100. Baxter Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 101. Baxter Latest Developments
Table 102. GSK Details, Company Type, Treatment of Chemotherapy-Induced Nausea in Cancer Patients Area Served and Its Competitors
Table 103. GSK Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
Table 104. GSK Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 105. GSK Main Business
Table 106. GSK Latest Developments
Table 107. Helsinn Details, Company Type, Treatment of Chemotherapy-Induced Nausea in Cancer Patients Area Served and Its Competitors
Table 108. Helsinn Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
Table 109. Helsinn Main Business
Table 110. Helsinn Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 111. Helsinn Latest Developments
Table 112. Southwest Pharma Details, Company Type, Treatment of Chemotherapy-Induced Nausea in Cancer Patients Area Served and Its Competitors
Table 113. Southwest Pharma Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
Table 114. Southwest Pharma Main Business
Table 115. Southwest Pharma Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 116. Southwest Pharma Latest Developments
Table 117. Haisco Details, Company Type, Treatment of Chemotherapy-Induced Nausea in Cancer Patients Area Served and Its Competitors
Table 118. Haisco Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
Table 119. Haisco Main Business
Table 120. Haisco Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 121. Haisco Latest Developments
Table 122. Sun Pharma Details, Company Type, Treatment of Chemotherapy-Induced Nausea in Cancer Patients Area Served and Its Competitors
Table 123. Sun Pharma Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Offered
Table 124. Sun Pharma Main Business
Table 125. Sun Pharma Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 126. Sun Pharma Latest Developments
List of Figures
List of Figures
Figure 1. Treatment of Chemotherapy-Induced Nausea in Cancer Patients Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Growth Rate 2017-2028 ($ Millions)
Figure 6. Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share by Type in 2021
Figure 7. Treatment of Chemotherapy-Induced Nausea in Cancer Patients in Acute CINV
Figure 8. Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market: Acute CINV (2017-2022) & ($ Millions)
Figure 9. Treatment of Chemotherapy-Induced Nausea in Cancer Patients in Delayed CINV
Figure 10. Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market: Delayed CINV (2017-2022) & ($ Millions)
Figure 11. Treatment of Chemotherapy-Induced Nausea in Cancer Patients in Breakthrough CINV
Figure 12. Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market: Breakthrough CINV (2017-2022) & ($ Millions)
Figure 13. Treatment of Chemotherapy-Induced Nausea in Cancer Patients in Others
Figure 14. Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market: Others (2017-2022) & ($ Millions)
Figure 15. Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share by Application in 2021
Figure 16. Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue Market Share by Player in 2021
Figure 17. Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share by Regions (2017-2022)
Figure 18. Americas Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size 2017-2022 ($ Millions)
Figure 19. APAC Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size 2017-2022 ($ Millions)
Figure 20. Europe Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size 2017-2022 ($ Millions)
Figure 21. Middle East & Africa Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size 2017-2022 ($ Millions)
Figure 22. Americas Treatment of Chemotherapy-Induced Nausea in Cancer Patients Value Market Share by Country in 2021
Figure 23. Americas Treatment of Chemotherapy-Induced Nausea in Cancer Patients Consumption Market Share by Type in 2021
Figure 24. Americas Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share by Application in 2021
Figure 25. United States Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Growth 2017-2022 ($ Millions)
Figure 26. Canada Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Growth 2017-2022 ($ Millions)
Figure 27. Mexico Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Growth 2017-2022 ($ Millions)
Figure 28. Brazil Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Growth 2017-2022 ($ Millions)
Figure 29. APAC Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share by Region in 2021
Figure 30. APAC Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share by Application in 2021
Figure 31. China Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Growth 2017-2022 ($ Millions)
Figure 32. Japan Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Growth 2017-2022 ($ Millions)
Figure 33. Korea Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Growth 2017-2022 ($ Millions)
Figure 34. Southeast Asia Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Growth 2017-2022 ($ Millions)
Figure 35. India Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Growth 2017-2022 ($ Millions)
Figure 36. Australia Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Growth 2017-2022 ($ Millions)
Figure 37. Europe Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share by Country in 2021
Figure 38. Europe Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share by Type in 2021
Figure 39. Europe Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share by Application in 2021
Figure 40. Germany Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Growth 2017-2022 ($ Millions)
Figure 41. France Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Growth 2017-2022 ($ Millions)
Figure 42. UK Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Growth 2017-2022 ($ Millions)
Figure 43. Italy Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Growth 2017-2022 ($ Millions)
Figure 44. Russia Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Growth 2017-2022 ($ Millions)
Figure 45. Middle East & Africa Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share by Region in 2021
Figure 46. Middle East & Africa Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share by Type in 2021
Figure 47. Middle East & Africa Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Market Share by Application in 2021
Figure 48. Egypt Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Growth 2017-2022 ($ Millions)
Figure 49. South Africa Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Growth 2017-2022 ($ Millions)
Figure 50. Israel Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Growth 2017-2022 ($ Millions)
Figure 51. Turkey Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Growth 2017-2022 ($ Millions)
Figure 52. GCC Country Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Growth 2017-2022 ($ Millions)
Figure 53. Americas Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size 2023-2028 ($ Millions)
Figure 54. APAC Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size 2023-2028 ($ Millions)
Figure 55. Europe Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size 2023-2028 ($ Millions)
Figure 56. Middle East & Africa Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size 2023-2028 ($ Millions)
Figure 57. United States Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size 2023-2028 ($ Millions)
Figure 58. Canada Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size 2023-2028 ($ Millions)
Figure 59. Mexico Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size 2023-2028 ($ Millions)
Figure 60. Brazil Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size 2023-2028 ($ Millions)
Figure 61. China Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size 2023-2028 ($ Millions)
Figure 62. Japan Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size 2023-2028 ($ Millions)
Figure 63. Korea Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size 2023-2028 ($ Millions)
Figure 64. Southeast Asia Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size 2023-2028 ($ Millions)
Figure 65. India Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size 2023-2028 ($ Millions)
Figure 66. Australia Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size 2023-2028 ($ Millions)
Figure 67. Germany Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size 2023-2028 ($ Millions)
Figure 68. France Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size 2023-2028 ($ Millions)
Figure 69. UK Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size 2023-2028 ($ Millions)
Figure 70. Italy Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size 2023-2028 ($ Millions)
Figure 71. Russia Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size 2023-2028 ($ Millions)
Figure 72. Spain Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size 2023-2028 ($ Millions)
Figure 73. Egypt Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size 2023-2028 ($ Millions)
Figure 74. South Africa Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size 2023-2028 ($ Millions)
Figure 75. Israel Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size 2023-2028 ($ Millions)
Figure 76. Turkey Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size 2023-2028 ($ Millions)
Figure 77. GCC Countries Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size 2023-2028 ($ Millions)
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets